Allison Dorval Sells Shares of Puma Biotechnology, Inc. $PBYI
Key Points
- Allison Dorval sold 11,610 shares of Puma Biotechnology, Inc. ($PBYI) worth $83,592.
- $PBYI last traded around $7.07.
Allison Dorval, insider at Puma Biotechnology, Inc. ($PBYI), sold 11,610 shares at an average price of $7.20, for a total transaction of $83,592. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Puma Biotechnology, Inc. ($PBYI) Stock
Puma Biotechnology, Inc. Earnings
Analysts Set New Price Targets
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.